External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients [1]

Journal of Acquired Immune Deficiency Syndromes

Volumn 42, Issue 1, 2006, Pages 127-128

  Marcelin, Anne Geneviève ^a   Chazallon, Corine ^b   Gérard, Laurence ^b   Saïdi, Yacine ^b   Aboulker, Jean Pierre ^b   Girard, Pierre Marie ^c   Calvez, Vincent ^a   Piketty, Christophe ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DIAGNOSTIC VALUE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PRIORITY JOURNAL; PROTEINASE INHIBITION; SCORING SYSTEM; TREATMENT OUTCOME; VALIDATION PROCESS;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SPECIES SPECIFICITY;

EID: 33745456769     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000219776.27798.e7     Document Type: Letter

References (12)

1. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7(3):165-174.
2. Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2004;48(12):4687-4692.
3. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother. 2003;47(2):594-600.
4. Valer L, de Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol. 2005;77(4):460-464.
5. Valer L, Gonzalez de Requena D, de Mendoza C, et al. Impact of drug levels and baseline genotype and phenotype on the virologie response to amprenavir/ritonavir-based salvage regimens. AIDS Patient Care STDS. 2004;18(1):1-6.
6. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther. 2004;9(4):465-478.
7. Brun-Vezinet F, Descamps D, Ruffault A, et al. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS. 2003;17(12):1795-1802.
8. Flandre P, Marcelin AG, Pavie J, et al. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir Ther. 2005;10(4):479-487.
9. Vora S, Marcelin AG, Gunthard HF, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor- experienced patients. AIDS. 2006;20(1):35-40.
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2005. Top HIV Med. 2005;13(4):125-131.
11. Piketty C, Gérard L, Chazallon C, et al. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Antivir Ther. 2006;11(2):213-221.
12. Colonno RJ, Thiry A, Limoli K, et al. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother. 2003;47(4):1324-1333.